Luminary licenses TcBuster CAR T tech from Bio-Techne

By The Science Advisory Board staff writers

February 23, 2021 -- Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the manufacturing of gene-modified cell therapies.

TcBuster is Bio-Techne's proprietary nonviral transposon-based gene delivery system designed to advance cell therapy manufacturing. The use of TcBuster during the manufacturing of cell therapies allows for delivery of larger cargo, according to the firms.

Under the agreement, Bio-Techne has granted Luminary with a nonexclusive license for TcBuster. Luminary will use the technology in its LMY-920 program, a B-cell activating factor (BAFF) CAR T-cell therapy. Luminary plans to file an investigational new drug application with the U.S. Food and Drug Administration later this year.

Financial details of the agreement were not disclosed.

Bio-Techne invests in China-based cell and gene therapy media company
Bio-Techne has made an initial minority strategic equity investment in Changzhou Eminence Biotechnology. The companies will synergistically work on the...
ScaleReady launches to improve T-cell manufacturing
A new joint venture called ScaleReady has been launched to develop tools and technologies for use in cell and gene therapy manufacturing. The firm is...
Bio-Techne opens GMP manufacturing facility
Bio-Techne has opened a 61,000-sq-ft good manufacturing practice (GMP) manufacturing facility in St. Paul, MN. The space will be dedicated to large-scale...
Bio-Techne rebrands genome engineering as part of R&D Systems portfolio
Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter